CEO Zenith Point Venures
- Image Source: Generated by ChatGPT / OpenAI image generation. Prompted by me.
- Canon Link: N/A
- Primary Source: Zenith Point Ventures
CORPORATION INFORMATION
- Corporation Name: ImperiaLabs
- Headquarters: Former Imperial cloning facilities, New Aldera, New Alderaan
- Locations: Official: New Alderaan, Drongar (Classified research blacksite), Por Raton - moon of Ingo (classified containment and accelerated growth facilities)
- Operations: Advanced genetic engineering, cloning sciences, medical regeneration technologies, accelerated tissue cultivation, behavioral imprinting research, military bioengineering, pharmaceutical development, long-term cryogenic preservation, and bespoke biological solutions for government and private-sector contracts.
- Parent Corporation: Zenith Point Ventures
- Subsidiaries: N/A
DESCRIPTION
ImperiaLabs is a cutting-edge genetics and bioengineering corporation headquartered on New Alderaan, operating under the corporate umbrella of Zenith Point Ventures. Publicly, the company presents itself as a premier provider of advanced medical cloning, regenerative therapies, and adaptive biological technologies for governments, private organizations, and wealthy clientele throughout the galaxy. Behind the polished corporate branding, however, ImperiaLabs is in truth the corporatized remnant of the former cloning initiatives once operated by both the Empire of the Lost and later the Imperial Confederation. Much of its infrastructure, institutional knowledge, and scientific talent were quietly absorbed into the new enterprise following the collapse and fragmentation of those governments.
The company inherited a mixture of brilliant scientific minds, ethically questionable data archives, and highly classified research methodologies originating from decades of Imperial experimentation. While many of the corporation’s projects remain legitimate in nature — including organ regeneration, anti-radiation treatments, battlefield medicine, and agricultural bio-adaptation — ImperiaLabs continues to maintain several heavily restricted blacksite facilities where more controversial research is conducted away from public scrutiny. These facilities on Drongar and Por Raton are rumored to house accelerated cloning chambers, experimental cognitive imprinting programs, and unstable genetic enhancement initiatives.
ImperiaLabs operates with a strict compartmentalized structure. Most employees possess access only to their immediate projects, limiting knowledge leaks and protecting proprietary research. The corporation aggressively pursues government and military contracts but also accepts private commissions from powerful individuals capable of paying its exorbitant fees. Officially neutral in galactic politics, ImperiaLabs nevertheless maintains longstanding relationships with numerous Imperial successor factions and corporate entities due to the origins of its personnel and technologies.
Despite its polished image and promises of responsible innovation, critics and watchdog organizations frequently accuse ImperiaLabs of concealing dangerous experimentation beneath layers of corporate bureaucracy and legal insulation. The corporation publicly denies such allegations, insisting that all research conducted under its authority adheres to “necessary ethical oversight standards for galactic advancement.”
RATIONALE
Nolle Tron, CEO of Zenith Point Ventures, acquired controlling interest in ImperiaLabs through a calculated corporate buyout after discovering fragmented reports regarding increasingly unstable experimentation occurring within the remnants of the former Imperial cloning apparatus. While the laboratories themselves possessed immense financial and scientific value, Nolle became particularly alarmed by the trajectory of research overseen by the company’s Chief Research Officer,
Loree Dangon
— more commonly known internally under the alias Dr. Aakiya Orime. Reports suggested that Orime’s work was beginning to move beyond conventional cloning science into highly dangerous territory involving cognitive replication, behavioral rewriting, and potentially uncontrollable biological adaptation.Recognizing both the opportunities and risks presented by the organization, Nolle used Zenith Point Ventures’ extensive financial influence to absorb the struggling network of laboratories before rival factions or rogue Imperial remnants could seize control of the facilities. Publicly, the acquisition was framed as a restructuring effort intended to preserve valuable medical and scientific technologies for legitimate galactic use. Privately, however, Nolle’s primary motivation was containment. She feared that left unchecked, ImperiaLabs could evolve into something catastrophically dangerous — particularly if Orime’s ambitions continued escalating without oversight.
Following the takeover, Zenith Point Ventures installed layers of corporate governance, internal auditing, and security review protocols throughout the company. Even so, Nolle remains aware that fully controlling ImperiaLabs may prove impossible. Too many projects remain buried beneath decades of classified Imperial research, and too many scientists within the organization still carry loyalties to older visions of Imperial superiority and engineered perfection.
For now, Nolle Tron walks a dangerous line: attempting to preserve the beneficial advancements ImperiaLabs can provide while preventing the corporation from becoming the next great horror born from the ashes of Imperial science.